Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.

@article{Molden2002PharmacokineticsOD,
  title={Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.},
  author={Espen Molden and Per Wiik Johansen and Grethe Helen B\oe and Stein Bergan and Hege Christensen and Hans Erik Rugstad and Helge Rootwelt and L{\'e}on Reubsaet and Gustav Lehne},
  journal={Clinical pharmacology and therapeutics},
  year={2002},
  volume={72 3},
  pages={333-42}
}
OBJECTIVES Recently, it was shown in vitro that the polymorphic enzyme cytochrome P450 (CYP) 2D6 mediates O-demethylation of diltiazem. The aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence… CONTINUE READING